Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents
Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents
复制标题
DOI：
10.3109/00952990.2014.983272
复制
发表时间：
2015-01-01
影响因子：
2.7
通讯作者：
Erdogan, Ayten
中科院分区：
文献类型：
--
作者：
Demirci, Arzu Ciftci;Gunes, Hatice;Erdogan, Ayten
Background: There are limited efficacy and safety data for buprenorphine/naloxone treatment in adolescents, and little is known about the incidence and prevalence of liver function abnormalities in young patients using buprenorphine/naloxone. Objectives: To assess the changes in liver enzyme levels associated with buprenorphine/naloxone treatment and co-medication with psychotropic agents among opioid dependent subjects aged 15-18 years. Methods: Liver enzyme levels (ALT and AST) were evaluated among 59 adolescent subjects before and following eight weeks of buprenorphine/naloxone treatment. Results: The frequency of additional psychotropic use was 60%. The patients' mean liver enzyme levels at weeks 2 and 4 were significantly higher than the baseline (ALT: p
